F008 Monitoring Guidelines for Immunomodulatory Drug Therapy
DESCRIPTION
In this session, we will review the latest and updated guidelines on the use, monitoring and contraindications for immunomodulatory medications. This will include traditional agents such as prednisone, azathioprine and mycophenolate mofetil, cyclosporine, as well as newer agents and biologics. The lectures will cover medication monitoring, including the selection of appropriate testing, identification of side effects.
LEARNING OBJECTIVES
Recognize risks and benefits of, and possible complications from immunomodulatory agents used to treat dermatologic diseases.
Select the appropriate screening and monitoring tests for patients who are treated with immunomodulatory medications.
Identify special considerations in the adolescent population, including supporting and coordinating vaccinations.
DIRECTOR
Adela Rambi G. Cardones, MD, FAAD
SPEAKERS
Ahmed Badawi, MD, PhD, FAAD
Anna Haemel, MD, FAAD
George K Hightower, MD, FAAD
Jesse J Keller, MD, MCR, FAAD
Ting Wang-Weinman, PhD, MD, FAAD
DISCLOSURES
Ahmed Badawi, MD, PhD, FAAD
Blueprint Medicines – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria);
Adela Rambi G. Cardones, MD, FAAD
Leo Foundation – Investigator(Grants/Research Funding);
Anna Haemel, MD, FAAD
AstraZeneca – Investigator(Fees); Celldex – Investigator(Grants/Research Funding); CSL Behring – Data Safety Monitoring Board(Honoraria); Eli Lilly – Stockholder Public Company(Stock); Galderma – Investigator(Grants/Research Funding); Insmed – Investigator(Fees); Priovant Therapeutics – Advisory Board(Honoraria), Investigator(Fees);
George K Hightower, MD, FAAD
No financial relationships exist with ineligible companies.
Jesse J Keller, MD, MCR, FAAD
Galderma USA – Speaker(Honoraria);
Ting Wang-Weinman, PhD, MD, FAAD
No financial relationships exist with ineligible companies.